(NYSEMKT: AIM) Aim Immunotech's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.47%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.48%.
Aim Immunotech's earnings in 2025 is -$15,750,000.On average, 3 Wall Street analysts forecast AIM's earnings for 2025 to be -$21,007,193, with the lowest AIM earnings forecast at -$21,669,401, and the highest AIM earnings forecast at -$20,461,107. On average, 3 Wall Street analysts forecast AIM's earnings for 2026 to be -$9,495,163, with the lowest AIM earnings forecast at -$12,106,904, and the highest AIM earnings forecast at -$6,770,440.
In 2027, AIM is forecast to generate -$4,639,449 in earnings, with the lowest earnings forecast at -$4,501,643 and the highest earnings forecast at -$4,823,189.